Australian medicinal cannabis distributor Health House has expanded its deal with Zelira Therapeutics to include cannabidiol (CBD) toothpaste in the UK.
The five-year exclusive agreement will Zelira, a leading medical cannabis developer of cannabinoid-based medicines for insomnia, autism and pain, commenced yesterday, the company said today.
The agreement further expands Health House’s portfolio of cannabis products in the UK.
Health House already has non-exclusive rights to distribute Zelira’s Zenivol and HOPE products throughout Australia, New Zealand and the UK.
Health House’s chief operating officer for the UK & Europe Tony Samios said the Zelira CBD toothpaste brand, manufactured by Springjene in the US, represents a “unique product offering” in oral healthcare.
“It is made up of patented formulation of zinc, black seed oil and CBD which are thought to fight conditions like gingivitis and reduce gum inflammation and to which the addition of CBD could make this even more effective,” he said.
“We are pleased to be able to bring this product into the UK market and distribute it to our range of clients.”
To retain exclusivity, Health House is required to purchase US$250,000 of Zelira’s CBD toothpaste in the first six months of the distribution agreement and US$500,000 in the first 12 months.
In Australia, it is fully licensed to import, export and distribute medicinal cannabis and Perth-based Health House has been distributing across Australasia, the UK and Europe since 2014.
The company was chosen by Zelira to distribute its products because of its established distribution networks in markets such as the UK, which could provide a launchpad to a global footprint.